A 58-year-old man with cirrhosis (Child-Pugh B) and a 3.5 cm solitary hepatocellular carcinoma in the right lobe, without vascular invasion or extrahepatic spread, presents for treatment planning. Which is the drug of choice for systemic therapy if he is not a candidate for curative resection or transplantation?

Explanation

## First-Line Systemic Therapy for Advanced HCC **Key Point:** Atezolizumab + bevacizumab (anti-PD-L1 + anti-VEGF) is the preferred first-line systemic regimen for unresectable HCC based on the IMbrave150 trial, which demonstrated superior overall survival and time-to-progression compared to sorafenib [cite:ASCO/NCCN HCC Guidelines 2023]. ### Mechanism of Action - **Atezolizumab:** Monoclonal antibody against programmed death-ligand 1 (PD-L1); restores anti-tumor immunity. - **Bevacizumab:** Anti-VEGF monoclonal antibody; inhibits angiogenesis and tumor vascularity. - **Synergy:** Dual checkpoint and angiogenic blockade improves response rates and survival. ### Evidence Hierarchy | Regimen | Trial | Primary Endpoint | Median OS | Status | |---------|-------|------------------|-----------|--------| | Atezolizumab + bevacizumab | IMbrave150 | ORR 27.3% | 13.8 months | **1st-line preferred** | | Sorafenib | SHARP | ORR 2.2% | 10.7 months | 1st-line alternative | | Lenvatinib | REFLECT | ORR 40.6% | 13.6 months | 1st-line alternative | **High-Yield:** Atezolizumab + bevacizumab is now the standard of care for unresectable HCC in patients with adequate performance status (ECOG 0–1) and preserved liver function (Child-Pugh A–B). **Clinical Pearl:** Sorafenib and lenvatinib remain acceptable alternatives if immunotherapy is contraindicated (active autoimmune disease, severe hepatic decompensation) or if the patient cannot tolerate combination therapy. **Warning:** Doxorubicin (transarterial chemoembolization [TACE]-based) is reserved for intermediate-stage HCC (BCLC stage B) and is NOT first-line systemic therapy for advanced disease.